Opaleye Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Opaleye Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,576	Closed	-$412K	–	51
2022 Q3	$412K	Buy	46,576 +25,056	+116%	+$208K	0.17%	37
2022 Q2	$166K	Buy	+21,520	New	+$172K	0.07%	46
2021 Q3	–	Sell	-382,000	Closed	-$3.82M	–	56
2021 Q2	$3.82M	Buy	382,000 +5,100	+1%	+$56.8K	0.63%	36
2021 Q1	$4.41M	Buy	376,900 +95,613	+34%	+$1.61M	0.65%	43
2020 Q4	$10M	Buy	281,287 +40,395	+17%	+$697K	1.31%	21
2020 Q3	$3.33M	Buy	+240,892	New	+$3.6M	0.65%	38

Other funds holding LUMO

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Opaleye Management's LUMO Position: Q4 2022 in Review

Opaleye Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2022, closing a stake of 46,576 shares — an estimated $412K sold.

Opaleye Management first reported a position in LUMO in Q3 2020 and held it in 6 quarters. The position peaked at $10M in Q4 2020. 37 funds tracked by Wall St. Rank hold LUMO as of Q4 2022.

Opaleye Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Opaleye Management sold 46,576 Lumos Pharma, Inc. Common Stock shares in Q4 2022, an estimated $412K.
Opaleye Management first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Opaleye Management's Lumos Pharma, Inc. Common Stock position peaked at $10M in Q4 2020.
37 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2022.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.